Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
Posted on: Tuesday, 29 September 2009, 14:31 CDT
IPSWICH, Mass., Sept. 29 /PRNewswire/ -- Dr. John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, and Dr. Kamran Shazand, Project Manager, of the Ontario Institute for Cancer Research (OICR) led a team of scientists who have completed a thorough evaluation of the NEBNext(TM) DNA Sample Prep Reagents for use with OICR's Illumina® Genome Analyzer II. Dr. McPherson said of the evaluation, "We are constantly striving for the best quality sequencing results at a price that does not restrict our throughput needs and NEB's new reagents meet this need well."
(Logo: http://www.newscom.com/cgi-bin/prnh/20090921/NE79207LOGO-b )
"We are extremely pleased that OICR, as a world leading genome center, has determined that our reagents meet their high standards," stated Dr. Peter Nathan, Director of Global Business Development at New England Biolabs.
NEBNext(TM) DNA Sample Prep Reagent Sets contain enzymes and buffers that are ideally suited for sample preparation for next generation sequencing, and for preparation of expression libraries. Reagents are available for each step of the library construction workflow, including end repair, dA-tailing, adapter ligation and amplification. These sets are highly cost effective and each of the components must pass rigorous quality control and validation, including independent third-party evaluation on the appropriate NGS platform.
About New England Biolabs (NEB)
Established in the mid 1970's, New England Biolabs, Inc. leads the industry in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genome research. NEB continues to expand its product offerings into areas related to PCR, cloning, expression and purification, and is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit (http://www.neb.com)
About Ontario Institute for Cancer Research (OICR)
The Ontario Institute for Cancer Research is a new innovative cancer research centre, moving Ontario to the forefront of discovery and innovation. It is dedicated to research in prevention, early detection, diagnosis and treatment of cancer. OICR is a not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. For more information about OICR, visit (http://www.oicr.on.ca)
SOURCE New England Biolabs
Source: PR Newswire
Related Articles
- Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus
- Researchers Decode 3D Structures Of The Human Genome
- Arcxis Biotechnologies and Roche Molecular Systems Initiate Research Collaboration to Apply New Technology for Diagnostic Sample Preparation
- Introgen to Present ADVEXIN Phase 3 Study Results at American Association for Cancer Research's Cancer Clinical Trials and Personalized Medicine Conference
- Researchers Piece Together First Draft Of Corn Genome
- Medistem Commences Pre-Clinical Research With Lawson Health Research Institute in London, Ontario in the Treatment of Autoimmune Diseases
- Many Turn to Internet for Cancer Research
- Power3 Makes Extensive Medical Research Available to Industry Partners; Database of Patient Samples is Basis for Identification of Protein Biomarkers
- Fox Chase Cancer Center Joins Dharmacon and International Research Institutes
- Pfizer and Perlegen Form New Genetics Research Collaboration to Analyze Patient DNA Samples
 |
 |
User Comments (0)
RSS Feeds